Zhang B, Shi C, Gao Z, Zhong H, et al. Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study). BMC Cancer 2022;22:294.
PMID: 35305596